We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Guidance on Expedited Pathways for Cell Therapies
FDA Issues Guidance on Expedited Pathways for Cell Therapies
The FDA released final guidance outlining the expedited pathways available to sponsors of regenerative medicine therapies — including considerations for clinical trial designs for treatments of rare diseases.